-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NFgD8AvFtvWimZ5UNXRZ1hAAjRFIfT9LY1DqGU+wJAmsfU++nUZ/aXtVYGRcN/rO
 0Wy3aowgDI0vlU1vuVI3GA==

<SEC-DOCUMENT>0000950148-02-001561.txt : 20020618
<SEC-HEADER>0000950148-02-001561.hdr.sgml : 20020618
<ACCEPTANCE-DATETIME>20020618164401
ACCESSION NUMBER:		0000950148-02-001561
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20020618
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20020618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADVANCED BIOTHERAPY INC
		CENTRAL INDEX KEY:			0000791833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26323
		FILM NUMBER:		02681660

	BUSINESS ADDRESS:	
		STREET 1:		6355 TOPANGA CANYON BLVD
		STREET 2:		SUITE 510
		CITY:			WOODLAND HILLS
		STATE:			CA
		ZIP:			91367
		BUSINESS PHONE:		8188833956

	MAIL ADDRESS:	
		STREET 1:		6355 TOPANGA CANYON BLVD
		STREET 2:		SUITE 510
		CITY:			WOODLAND HILLS
		STATE:			CA
		ZIP:			91367

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED BIOTHERAPY CONCEPTS INC
		DATE OF NAME CHANGE:	19990524
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v82473e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc.  Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P><FONT size="2">Date of Report (Date of earliest reported) June&nbsp;18, 2002
</FONT>
<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>
<HR width="26%" align="center" size="1" noshade>

<DIV align="center"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></DIV>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="34%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="28%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">Delaware</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">0-26323</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2"><HR size="1" noshade></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top" nowrap><FONT size="2">(State or other jurisdiction<BR>of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top" nowrap><FONT size="2">(Commission<BR>File Number)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top" nowrap><FONT size="2">(IRS Employer<BR>Identification No.)</FONT></TD>
</TR>
</TABLE>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="51%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="21%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="22%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top" nowrap><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>Woodland Hills,  California</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="bottom"><FONT size="2">91367</FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><FONT size="2"><HR size="1" noshade></FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top" nowrap><FONT size="2">(Address of principal executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap valign="top" nowrap><FONT size="2">(Zip Code)</FONT></TD>
        <TD align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
<P><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="v82473exv99w1.htm">exhibit 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on June&nbsp;17, 2002, which announced
that it had raised approximately $3,667,000 in the private placement of its
subordinated convertible pay-in-kind notes during approximately two months
ended June&nbsp;14, 2002, and that the registrant has decided to file for Phase I
Investigational New Drug Applications (IND&#146;s) with the US Food and Drug
Administration for two specific autoimmune diseases. A copy of such press
release is incorporated herein by reference and is attached as an exhibit to
this Form&nbsp;8-K.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
   <TD width="1%" align="right" nowrap><FONT size="2">(c)</FONT></TD>
   <TD width="1%" nowrap><FONT size="2">&nbsp;&nbsp;</FONT></TD>
   <TD width="98%"><FONT size="2">Exhibits.</FONT></TD>
</TR>
</TABLE>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="12%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="83%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Press Release, dated June&nbsp;17, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="50%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="top">
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD colspan="2"><FONT size="2">ADVANCED BIOTHERAPY, INC.<BR>(Registrant)</FONT></TD>
</TR>

<TR><TD>&nbsp;<BR>&nbsp;</TD></TR>
<TR valign="top">
        <TD><FONT size="2">Date: June&nbsp;18, 2002</FONT></TD>
        <TD><FONT size="2">By:&nbsp;</FONT></TD>
        <TD align="left"><FONT size="2">/s/ Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD colspan="2"><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade color="#000000"></TD>
</TR>
<TR valign="top">
        <TD colspan="2">&nbsp;</TD>
        <TD><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="55%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated June&nbsp;17, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v82473exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="right"><FONT size="2">EXHIBIT 99.1</FONT>

<P align="center"><FONT size="2"><B>Advanced Biotherapy, Inc. Reports on Capital Formation and Plans to Conduct<BR>
Phase I Clinical Trials in the U.S.</B></FONT>

<P><FONT size="2">WOODLAND HILLS, CA.&#151; (BW HealthWire)&#151;June&nbsp;17, 2002&#151; Advanced Biotherapy, Inc.
(OTCBB: ADVB &#151; news) announced today that it had raised approximately
$3,667,000 in the private placement of its subordinated convertible pay-in-kind
notes during approximately two months ended June&nbsp;14, 2002. The convertible
notes bear interest at 11% per year payable in cash or additional convertible
debt, and are convertible into shares of Company Common Stock at a conversion
price of $0.25 per share, subject to certain anti-dilution rights. The
convertible notes were placed in two series with the first maturing on
September&nbsp;30, 2004, of which approximately $1,147,000 was placed, and the
second maturing on June&nbsp;1, 2006, of which approximately $2,520,000 was placed
during June 2002. Commenting on this announcement, Mr.&nbsp;Edmond Buccellato,
President and Chief Executive Officer stated &#147;This infusion of capital,
combined with the strength of our intellectual property, will allow us to
implement our business plan regarding the conduct of clinical trials in the
U.S.&#148;
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of proceeds raised from the placement of its convertible debt
during the month of June, 2002, the Company has decided to file for Phase I
Investigational New Drug Applications (IND&#146;s) with the US Food and Drug
Administration for two specific autoimmune diseases. An IND may be submitted
for one or more phases of an investigation. The clinical investigation of a
previously untested drug is generally divided into three phases. Phase I, the
initial phase, includes the initial introduction of an investigational new drug
into humans. Phase I studies are typically closely monitored and may be
conducted in patients or normal volunteer subjects. These studies are designed
to determine the metabolism and pharmacologic actions of the drug in humans,
the side effects associated with increasing doses, and, if possible, to gain
early evidence on effectiveness. At this stage, the Company intends that such
clinical investigations will be conducted under a contractual arrangement with
one or more clinical research organizations, although no such arrangements have
been made. Advanced Biotherapy, Inc., is also beginning to pursue out-licensing
agreements for the use of antibodies to interferon-gamma to treat certain
autoimmune conditions.
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements made in this news release, other than statements of historical
fact, are forward-looking statements and are subject to a number of
uncertainties that could cause actual results to differ materially from the
anticipated results or other expectations expressed in our forward-looking
statements. The risks and uncertainties which may affect the development,
operations and results of our business include, but are not limited to the
following: risks associated with clinical trials, the uncertainties of
research and product development programs, the uncertainties of the regulatory
approval process, the risks of competitive products, the risks of our current
capital resources, the uncertainties as to the availability of future capital
and our future capital requirements, and the risks associated with the extent
and breadth of the Company&#146;s patent portfolio. The rights of the Company in
patents issued to the Company and applications for patents pending involve
risks and uncertainties, including, but not limited to, the risks that third
parties may be successful in challenging the patent; or that granted claims may
be held invalid or interpreted differently by a court of law; or that new
technologies will be developed that are superior in treating the diseases
targeted by Advanced Biotherapy, Inc. Readers are cautioned not to place
reliance on these forward-looking statements, which speak only as of the date
the statements were made. See the Company&#146;s public filings with the Securities
and Exchange Commission for further
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">information about risks and uncertainties
that may affect the Company and the results or expectations expressed in our
forward-looking statements, including the section captioned &#147;Factors That
May Affect The Company&#148; contained in the Company&#146;s Annual Report on Form&nbsp;10-KSB
for the fiscal year ended December&nbsp;31, 2001.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="5%">&nbsp;</TD>
        <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD colspan="2" valign="top"><FONT size="2">CONTACT:</FONT></TD>
</TR>

<TR valign="bottom">
        <TD colspan="2" valign="top"><FONT size="2">Edmond Buccellato</FONT></TD>
</TR>

<TR valign="bottom">
        <TD colspan="2" valign="top"><FONT size="2">President and CEO</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Email:&nbsp;&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">ed@advancedbiotherapy.com</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Telephone:&nbsp;&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">818-883-6716</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Website:&nbsp;&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">www.advancedbiotherapy.com</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
